2•ctivation
of CD4 + T cells by their target antigens and APC induces a cascade of differentiation events that result primarily in the secretion of IL-2. During the subsequent course of the immune response, CD4 + T cells may differentiate into IL-2 and IFN-3, secreting Thl-like cells or IL-4/IL-5/IL-10 secreting Th-2 like calls (1, 2) . Thus, T call activation by antigen and APC initiates not only effector T cell functions, but also programs the lymphokine pattern that primed T cells secrete during subsequent interactions with thdr target antigens. Although a number of factors have been proposed (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) to regnlate the type of lymphokine produced, it appears that lymphokines themselves may play the most dominant role in the regulation of the capacity of naive T cells to differentiate into Thl-or Th2-like populations (9) (10) (11) (12) .
The requirements for the induction of the IL-4 pathway have been extensively characterized in vitro (8) (9) (10) (11) (12) . The capacity to produce IL-4 is not a predetermined characteristic of a subpopulation of CD4 + T calls, but reflects a differentiation event during the process of T cell activation (2) . The presence of IL-4 at the time of stimulation of T cells with either polyclonal activators or specific antigen results in the priming of T cell populations which, when restimulated, produce high levels of IL-4, but little or no IL-2 or IFN-3,. Conversely, activation of resting T cells in the absence of IL-4 results in the priming for IFN-3, production and this priming can be blocked by the presence of IL-4. Although IL-4 can readily be induced in vivo with polyclonal stimulators (8) (9) (10) (11) (12) such as injection of anti-IgD or parasite infection, the specific signals needed to induce IL-4 could not be readily analyzed. Induction of IL-4 can be diminished by treatment of animals with anti-IL-4, suggesting that IL-4 is also required for its own induction in vivo (4, (14) (15) (16) (17) .
Although progress has been made in understanding the regulation of the induction of cytokine production, much less is known and considerable controversy exists regarding the requirements for the induction of nonresponsiveness or anergy in Thl-and Th2-1ike CD4 + T cells. CD4 + Thl clones can be easily rendered anergic by culture with antigenpulsed, fixed APC or plate-bound anti-CD3, whereas similar treatment of Th2 clones results in no diminution of their capacity to produce IL-4 (18) (19) (20) (21) (22) (23) . It is difficult to generalize from these studies of T cell clones as to the requirements for the tolerization of naive CD4 + T cells in vitro because the protocols developed for use with clones are rdatively ineffective in the induction of anergy in naive or short-term stimulated T calls. Studies in vivo have similarly demonstrated that those strategies that permit the induction of tolerance, such as the injection of deaggregated human IgG or high doses of hapten-protein conjugates, result in a selective deficiency of antigen-specific proliferation, IL-2, and IFN-3, production, but prime rather than tolerize IL-4-producing cells (24) (25) (26) . Taken together, these as weU as other studies (27) (28) (29) strongly suggest that the IL-4 pathway is profoundly resistant to tolerance induction both in vitro and in vivo, or alternatively, that the conditions for the induction of tolerance in Th2-1ike cells have not yet been defined.
Here we use the superantigen, Staphylococcus enterotoxin A (SEA), 1 as a model antigen to characterize the signals that regulate the IL-4 pathway in vivo. In BALB/c mice, SEA selectively activates TCR V31 + and V310 + T cells (30) , without detectable priming for IL-4. First, we demonstrated that administration of IL-4 during the period of T ceU activation with SEA was required to prime T cells in vivo for IL-4 production. We then tested the responsiveness of the IL-4 pathway to tolerogenic signals in vivo. It is surprising that the IL-4 pathways of both naive and primed T cells were highly susceptible to tolerance induction. Lastly, the restoration of the IL-4 pathway in tolerant T cells required polyclonal activation and expansion of the tolerant population, whereas those stimuli which were effective in priming naive T cells for IL-4 production failed to induce IL-4 in tolerant T cells.
Materials and Methods
Animals. Vires In Vivo Treatment. Mice were primed by a single subcutaneous injection of 50/~g SEA. Immediately after the first injection and 1Abbreviation used in this paper: SEA, Staphylococcus enterotoxin A.
subsequently every 8 h, the mice received the indicated dose of IL-4 intraperitoneally. SEA-specific tolerance was induced by a single subcutaneous injection of 100/zg SEA. In selected experiments, animals were infected subcutaneously at the indicated time with 700 third stage larvae ofN. bras/l/ens/s as previously descnl~l (14, 29) .
Pnpatau'on ofTCells and Accessory (?,elk Mesenteric lymph nodes and spleens were isolated and depleted of erythrocytes by lysis with ACK buffer. The cells were then incubated with anti-CDS, washed, and CD4+-enriched cells isolated by passage over mouse T cell columus (Biotex, Edmonton, Alberta, Canada). The resultant preparations were highly enriched in CD4 + cells and contained no detectable CD8 § cells. Accessory cells were prepared from the spleen of untreated, syngenic mice. After lysis with ACK lysing buffer, the cells were incubated with anti-CD8, anti-CD4 mAb, and antiThy 1.2, washed, and subsequently incubated for 45 min at 37~ with rabbit C (Cedarhne, Westbttry, NY). These preparations contained no detectable CD4 + or CD8 + ceils. Before use, accessory cells were irradiated with 3,000 rad from a Cesium source.
In Vitro Stimulation. CD4+-enriched cells were seeded in 96-well plates at three different cell numbers (0.25, 0.5, and 106 cells) together with 103 accessory cells in 250 #1 of DMEM medium supplemented with 10% heat inactivated FCS (Biofluids, Inc., Rockville, ME)), t-glutamine (2 mM), 2 B-ME (0.05 mM), sodium pyruvate (1 mM), penicillin (100 U/ml), and streptomycin (100/~g/ml). Cells from each ~perimental group were cultured with media alone, with SEA (10/zg/ml), or with SEB (10/~g/ml) in the presence of rIL-2 (5 U/ml). 
Results

Induction of Antigen-specific IL-4 Production
In Viv~ Based on in vitro studies which demonstrate that induction of IL-4 production in CD4 + T cells requires both a TCR-mediated stimulus and IL-4, we speculated that the combined administration of nontolerogenic doses of SEA and IL-4 should upregulate the IL-4 pathway in vivo. Animals were primed with a single injection of SEA (50/xg) and treated on days 0-2 with IL-4 (1/~g every 8 h). Control animals received SEA alone, IL-4 alone, or no treatment. On day 6 after priming, CD4 + T calls were isolated from both lymph nodes and spleen and evaluated for lymphokine production in vitro after stimulation with either SEA or SEB. CD4 + T cells from untreated animals or animals treated with SEA alone or IL-4 alone produced no detectable IL-4 when stimulated in vitro ( Fig. 1, A and B) . In sharp contrast, CD4 + T cells isolated from animals primed with SEA and IL-4 produced large amounts of IL-4 when restimulated in vitro with SEA. In 10 independent studies, IL-4 production was upregulated between 100-and 1,000-fold. IL-4 was induced sdectively in SEA-responsive T calls since SEB-responsive T ceils from the same animals produced no detectable IL-4 when challenged in vitro (Fig. 1, A and B) . Induction of IL-4 production was not observed at doses of IL-4 <1/zg every 8 h (Fig. 1 B) .
The (Fig. 2) . Previous studies have shown that the induction of IL-4 production in vitro or in vivo requires 3-6 d of stimulation. After priming with SEA and IL-4, SEA-specific IL-4-producing CD4 + T cells were first detectable after 3 d and peak levels of IL-4 production were observed between days 6 and 10 ( Fig. 3 A) . In most experiments, the capacity to produce IL-4 declined sharply between days 10 and 14. This sharp decline in CD4 +, SEA-responsive, IL-4-producing T ceils could either be due to a downregulation of the IL-4 pathway or could be secondary to a ddetion of the CD4 +, SEA responsive (V~10) population. However, as shown in Table  1 , the sharp decline in SEA-specific IL-4-producing T cells was never associated with a detectable decrease in CD4+VB10 + T cells. These kinetic studies suggested that the capacity of SEA and IL-4 to induce IL-4-producing T calls is only transient, and that the continuous presence of the inducing stimuli is required for maintenance of the pathway. To directly test this possibility, we injected animals a second time with the stimuli originally required to activate the IL-4 pathway in CD4 + T cells. Repriming of the animals with SEA and IL-4 prevented downregulation of the IL-4 pathway (Fig. 3 B) . with a downregnlation of IL-2 production (2-4, 8, 11 ). To determine whether the priming regimen of superantigen and IL-4 activated IL-4 production independently of suppression of the IL-2 pathway, we measured IL-2 production by CD4 § T cells from animals primed with SEA alone or primed with SEA and IL-4. Injection of mice with 50/~g of SEA alone resulted in a 10-fold reduction of IL-2 production in response to SEA. A decline of similar magnitude was seen in the production of IFN-3, and IL-3 (data not shown). However, SEA-specific IL-2 production was still 10 times higher than background, and injection of animals with the combination of SEA and IL-4 did not further diminish the capacity to produce IL-2 (Fig. 4) . The two concentrations of IL-4 used in this study resulted in an increase of II.-4 production of two to three orders of magnitude (Fig. 1 B) . Tolerization of the IL-4 Pathuny. The ability to generate a potent SEA-specific IL-4 response in vivo allowed us to directly investigate whether superantigen-induced tolerance only affects the IL-2 pathway or whether superantigens also tolerize the II,-4 pathway. We first injected BALB/c mice with a tolerogenic dose of SEA (100/~g) and 5 d later treated the animals with the priming regimen of SEA and IL-4. Pretreatment of mice with tolerogenic doses of SEA completely abolished their response to a subsequent treatment with SEA and IL-4 (Fig. 5 A) . To determine if the IL-4 pathway is also sensitive to tolerizing signals applied during the induction phase, mice were primed with SEA (50/~g) and IL-4, but then received two additional injections of SEA (50/~g) on days 3 and 6. When CD4 + T cells from these animals were restimulated in vitro, they produced no detectable IL-4 in response to SEA (Fig. 5 B) . This downregnlation of the IL-4 to Fig. 1. (B) BALB/c mice were primed with SEA and 11.,4 as in A or received no treatment. One group of the animals that had been primed with SEA and II.-4 received a second treatment with SEA (50/zg) and II,4 (1/~g every 8 h for 3 d), starting on day 7. On day 13, CD4 + cells were isolated and assayed for SEA-specific IL4 production. pathway was not prevented by additional treatment with IL-4 (until day 6; data not shown). The downregnlation of IL-4 production was also not secondary to deletion of SEAresponsive CD4 + T cells, since animals that received one single or repetitive injections of SEA had similar percentages of SEA-responsive CD4 + V~10 + T cells in lymph nodes or spleen between days 6 and 12 after injection of SEA (Table  1 and data not shown).
Effect of
As the ability of Th2 or Th0 T cell clones to produce IL-4 is resistant to tolerogenic signals in vitro (20, 22, 23) , it was of interest to examine in vivo the susceptibility of CD4 + T cells that had been primed for IL-4 production to tolerogenic signals. Mice were therefore primed with SEA and IL-4 and on day 6 after treatment, when IL-4 induction is maximal (Fig. 3 A) , mice received a second injection of SEA (50 ~g). It is surprising that CD4 + T cells from mice that received a second injection of SEA on day 6 produced <1% of the IL-4 produced by T cells from control animals that were primed in identical fashion, but that did not receive the second injection of SEA (Fig. 5 C) . cells from SEA-tolerant mice were not capable of producing IL-4 in response to SEA, whereas IL-4 was readily detected in SEB-responsive control populations (Fig. 6 A) . However, on day 9 after infection, CD4 + T cells from SEA-tolerant mice produced large amounts of IL-4 when challenged with SEA (Fig. 6 B) . Although the absolute amount of IL-4 produced by CD4 + cells from tolerant animals was still about fivefold lower than the amount of IL-4 produced by CD4 + cells from control animals, IV. brasiliensis infection induced more than a 100-fold increase in SEA-specific IL-4 production in the tolerant animals (Fig. 6 B) . There was a close correlation between the magnitude of parasite-induced lymphoproliferation and the reversion of SEA-specific tolerance. At day 7 after the infection, the number of lymph node cells was only moderately increased, whereas the number of lymph node cells increased 3.5-fold during the next 2 d of infection (Fig. 6, A and B) . However, the percentage of CD4+VB10 + T cells was constant (data not shown) during the entire period of infection with N. brasiliensis, indicating in vivo expansion
Discussion
Previous studies in vitro have strongly implied that one of the most critical factors that determines the differentiation of resting T cells into Th2-1ike IL-4--producing cells is IL-4 itself (8) (9) (10) (11) (12) . We have analyzed the immune response to the superantigen, SEA, to determine the requirements for the induction of a Th2-like response in vivo. Priming of animals with SEA together with IL-4 resulted in a marked upregulation of SEA-specific Th2-like ceils. Administration of either antigen alone or IL-4 alone failed to prime for IL-4 production. The induction of IL-4 was completely specific for the superantigen injected as no IL-4 production was seen in response to the control superantigen, SEB. When mice were injected with IL-4 for 3 d after priming with SEA, our ability to detect IL-4-producing T cells in vitro persisted until days 10-12, but not longer. It is unlikely that the waning of the IL-4-producing population was secondary to deletion of the superantigen-specific T cells, as no deletion of the SEAresponsive V~ populations was observed. Continued administration of IL-4 and SEA was required to maintain the Th2-like cells in vivo.
The requirement of IL-4 for the priming of Th2 cells in vivo is quite consistent with the results of studies that have used polydonal inducers of IL-4 production and anti-IL-4 mAbs to define the role of IL-4 in priming for Th2-like responses (15, 17, 33) . However, very few studies have attempted to characterize in vivo the signals required for the induction of IL-4 in normal CD4 § T cells. Chatelain et al. (34) have shown that injection of healer C3H mice with IL-4 locally into Leishraania-infected footpads results in an increased production of IL-4 and IL-5, but a decreased production of IFN-3', by draining lymph node cells harvested 48 h later. However, this shift in cytokine production was only transient, and all animals were ultimately able to heal their infections and produced Thl-like responses upon in vitro challenge.
Although our studies define the minimal requirements for the induction of IL-4 in normal T cells, it should be emphasized that it is very difficult to rule out the involvement of other cytokines particularly, IL-2, in the differentiation of SEA-specific Th2-like cells in vivo. A number of in vitro studies have suggested that IL-2 is required both for the induction and production of IL-4 (10, 12, 29, 35) . The concentration of SEA we used for the induction of IL-4 was only partially tolerogenic, and SEA-responsive T cells were still capable of producing measurable amounts of IL-2 when stimulated in vitro with SEA. Thus, sufficient IL-2 may have been generated after injection of SEA and IL-4 to facilitate induction of IL-4 in CD4 + T cells. Alternatively, it is possible that in vivo, other cytokines can substitute for IL-2, as recently suggested by studies with mice with targeted disruption of the IL-2 gene (36) . In preliminary experiments, we have observed that treatment of mice with anti-IL-2 or with cyclosporin A at the time of priming with SEA and IL-4 did of the SEA-responsive T cells. As previously reported (29) , induction of IL-4 production was not accompanied by detectable SEA-specific IL-2 production (data not shown).
not inhibit the generation of SEA-specific IL-4-producing T cells.
Our ability to specifically prime superantigen-specific IL-4-producing T cells in vivo allowed us to directly examine if IL-4-producing T cells could be tolerized in vivo. When SEA was first administered in a tolerogenic dose, our ability to prime for IL-4-producing T cells with SEA and IL-4 was completely abrogated. It is surprising that tolerance could also be induced in primed IL-4-producing cells. This dramatic susceptibility of Th2-1ike cells to tolerance induction is at marked variance with studies on Th2 and Th0 T cell clones in vitro in which the production of IL-4 is resistant to tolerogenic signals (22) . It should be emphasized that our studies do not allow any conclusions to be drawn about the mechanism of induction of Th2-1ike T cell tolerance. As noted above, induction and expansion of Th2-1ike T cells in vivo may require IL-2, and the tolerization protocols used in our studies may tolerize the IL-2 pathway and thus inhibit the development or continued expansion of Th2-1ike T cells. IL-4 production by Th2 or Th0 clones in vitro may be independent of IL-2 and therefore resistant to the induction of tolerance.
Considerable controversy exists as to whether tolerogenic signals can silence the IL-4 pathway in vivo. Some studies have demonstrated that injection of mice with high concentrations of antigen, which results in suppression of IL-2 and IFN-'y production, primes for IL-4 production (24-26), whereas other studies have shown that similar treatment inhibits the development of IL-4-producing cells and decreases antibody production after administration of the peptide antigen in adjuvant (37, 38) . Our data strongly suggest that induction or inhibition of IL-4 production critically depends on the dose of antigen as well as the amount of IL-4 supplied during T cell stimulation. One single injection of SEA (50 #g) together with IL-4 primed T cells for optimal IL-4 production, whereas two additional injection of SEA (50 #g) completely inhibited the development of IL-4-producing T cells. Similarly, CD4 + T cells that had been primed for IL-4 production could be readily tolerized by reinjection of SEA, but this SEA-induced downregulation could be prevented by the simultaneous administration of IL-4. The susceptibility of primed Th2-1ike cells to tolerance induction in vivo has important implications for the design of therapeutic strategies for the immunomodulation of allergic diseases.
Our ability to reprodudbly tolerize Th2-1ike cells afforded us the opportunity to reexamine the requirement for breaking T cell tolerance in vivo. We have previously shown that N. brasiliensis infection of animals tolerized with SEB resulted in a normal expansion of SEB-specific CD4+VB8 + T ceils in vivo as well as an equivalent increase of SEB-reactive IL-4-producing T cells (29) . We interpreted these studies as indicating that SEB injection rendered the IL-4-producing T cell population tolerant and that infection with N. brasiliensis resulted in breaking of the tolerant state by the induction of IL-4 in SEB-tolerant T calls. However, since we could not directly demonstrate that we had tolerized the IL-4 pathway in SEB-responsive calls, we could not exclude the possibility that infection with N. brasiliensis resulted in activation of a previously silent, but not tolerant, Th2-1ike population. The results of the present experiments directly demonstrate that infection with N. brasiliensis can break an established T cell tolerance. However, the signals required to induce IL-4 production in normal T ceils, antigen and IL-4, were not capable of reversing SEA-specific tolerance in vivo. Furthermore, we could demonstrate that the major parameter that correlated with the capacity of infection with N, brasiliensis to break tolerance was the magnitude of the lymphoprolfferation seen during the course of the infection. Thus, expansion of tolerant T 09-41) and B (42) calls appears to be one of the ways in which tolerance can be reversed in both T and B cells. Indeed, the polydonal expansion of tolerant T cells seen during the course of infectious diseases or treatment with high doses of IL-2 may reactivate tolerized lymphokine pathways and has resulted in the induction of autoimmunity (43) .
Although some studies suggest that the differentiation of CD4 + T cells into Thl-or Th2-1ike subpopulations is established at the time oft cell priming and may become fixed in a short period of time (33), we have shown that Thl-like T cell clones can still be converted into Th2-1ike cells after 3 wk of culture (2) . Similarly, during the course of an autoimmune disease, autoreactive T ceils are continuously being generated and the administration of IL-4 might influence the lymphokine phenotype of these newly produced T cells. In this regard, we (Racke, M. K., A. Bonomo, D. E. Scott, B. Cannella, A. D. Levine, C. S. Paine, E. M. Shevach, and M. Krcken, manuscript submitted for publication) have recently shown that the induction of experimental allergic encephalomyelits by the transfer of Thl-like T lines can be markedly inhibited by the administration of IL-4 at the time of cell transfer. The beneficial effects of the administration of IL-4 are associated with the generation of a myelin basic protein-specific population of IL-4--producing cells in the recipients.
